The dual FAAH/MAGL inhibitor JZL195 elevated both anandamide and 2-AG in rat brains and produced stronger motor-suppressing effects than the MAGL-only inhibitor JZL184.
Read this if you want to understand how drugs that boost endocannabinoids work differently across species.
JZL184 elevated 2-AG in rats but its motor effects were CB1-independent, unlike in mice
What the researchers found
JZL184, a selective MAGL inhibitor, was able to elevate brain 2-AG levels in rats, contrary to some previous reports suggesting it was ineffective in this species. However, the motor suppression caused by JZL184 was found to operate through a CB1-independent mechanism.
The dual FAAH/MAGL inhibitor JZL195 produced enhanced effects compared to JZL184 alone, simultaneously elevating both anandamide (via FAAH inhibition) and 2-AG (via MAGL inhibition) in the brain. Its behavioral effects, including motor suppression, were more robust than JZL184.
The finding that JZL184's behavioral effects in rats were CB1-independent is notable, as its effects in mice are CB1-dependent, highlighting important species differences in endocannabinoid pharmacology.
Why it matters
Understanding species differences in endocannabinoid pharmacology is critical for translating preclinical findings to humans. The rat is generally considered more predictive of human drug responses than the mouse, so clarifying how endocannabinoid-targeting drugs work in rats is essential for drug development.
The numbers in context
JZL184 elevated 2-AG in rat brain but its motor effects were CB1-independent. JZL195 elevated both anandamide and 2-AG and produced enhanced behavioral effects. Species differences noted between rat and mouse responses.
How the study worked
Researchers compared the neurochemical and behavioral effects of JZL184 (MAGL inhibitor) and JZL195 (dual FAAH/MAGL inhibitor) in rats. Brain endocannabinoid levels were measured after systemic drug administration. Behavioral assessments focused on motor activity. CB1 receptor involvement was tested using antagonist pre-treatment.
What this study cannot tell us
This was an animal study with limited behavioral measures (primarily motor activity). The CB1-independent mechanism of JZL184 in rats was not fully characterized. The doses used may not be directly relevant to human pharmacology. The study focused on acute administration and did not assess chronic effects.
How to read the evidence
This is a preclinical pharmacology study in rats. It provides important methodological clarifications for the field.
When this study was published
Published in 2014. Endocannabinoid enzyme inhibitor pharmacology continues to be refined.
The bigger picture
Endocannabinoid-modulating drugs are being developed as potential treatments for pain, anxiety, and other conditions. This study clarifies the pharmacology of key research tools in rats, an important preclinical species, and demonstrates that dual inhibition of both major endocannabinoid-degrading enzymes produces stronger effects than targeting either alone.
Questions still open
- What is the CB1-independent mechanism by which JZL184 suppresses motor activity in rats? Would dual enzyme inhibition produce stronger therapeutic effects in humans? Are there safety concerns with simultaneously elevating both endocannabinoids?
Common questions
Why do species differences matter?
What is the advantage of dual enzyme inhibition?
Read the original research
The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184.
Pharmacology, biochemistry, and behavior, 124, 153-9
Citation
Seillier, Alexandre; Dominguez Aguilar, David; Giuffrida, Andrea. (2014). The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184.. Pharmacology, biochemistry, and behavior, 124, 153-9. https://doi.org/10.1016/j.pbb.2014.05.022
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)